顺铂联合重组人5型腺病毒腹腔灌注治疗胃癌合并恶性腹腔积液的临床疗效  

Clinical efficacy of cisplatin combined recombinant human adenovirus type 5 intraperitoneal perfusion in the treatment of gastric cancer complicated with malignant ascites

作　　者：刘宏根[1] 赵林林[1] 杨佩颖[1] 赵成[1] 孔凡铭[1] LIU Honggen;ZHAO Linlin;YANG Peiying;ZHAO Cheng;KONG Fanming(Department of Oncology,First Teaching Hospital of Tianjin University of Traditional Chinese Medicine/National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion,Tianjin 300381,China)

机构地区：[1]天津中医药大学第一附属医院/国家中医针灸临床医学研究中心肿瘤科,天津3003810

出　　处：《癌症进展》2024年第5期520-523,539,共5页Oncology Progress

基　　金：天津市教委科研计划项目(2018KJ015)。

摘　　要：目的探讨顺铂联合重组人5型腺病毒(H101)腹腔灌注治疗胃癌合并恶性腹腔积液的临床疗效。方法采用随机数字表法将68例胃癌合并恶性腹腔积液患者分为顺铂组(n=34,顺铂腹腔灌注)和顺铂联合H101组(n=34,顺铂联合H101腹腔灌注)。比较两组患者的腹腔积液缓解情况、腹腔积液间隔时间、生存情况、生活质量及不良反应发生情况。结果顺铂联合H101组患者腹腔积液总缓解率为73.5%,高于顺铂组患者的50.0%,差异有统计学意义(P﹤0.05)。顺铂联合H101组患者腹腔积液间隔时间为(34.02±9.79)天,明显长于顺铂组患者的(27.56±9.36)天,差异有统计学意义(P﹤0.01)。顺铂联合H101组患者的中位总生存期长于顺铂组(P﹤0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P﹥0.05)。结论顺铂联合H101腹腔灌注治疗胃癌合并恶性腹腔积液患者,能够安全有效地控制腹腔积液生成,改善患者的生活质量,延长患者的生存期。Objective To explore the clinical efficacy of cisplatin combined recombinant human adenovirus type 5(H101)intraperitoneal perfusion in the treatment of gastric cancer complicated with malignant ascites.Method A total of 68 patients with gastric cancer complicated with malignant ascites were divided into cisplatin group(n=34,received cisplatin intraperitoneal perfusion)and cisplatin combined with H101 group(n=34,received cisplatin combined H101 intraperitoneal perfusion)by random number table method.The response of ascites,interval of ascites,survival,quality of life and adverse reactions were compared between the two groups.Result The overall response rate of ascites in cisplatin combined with H101 group was 73.5%,which was higher than 50.0%in cisplatin group,and the difference was statistically significant(P<0.05).The interval of ascites in cisplatin combined with H101 group was(34.02±9.79)days,which was significantly longer than(27.56±9.36)days in cisplatin group,and the difference was statistically significant(P<0.01).The median overall survival in cisplatin combined with H101 group was longer than that in cisplatin group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Cisplatin combined H101 peritoneal perfusion in the treatment of patients with gastric cancer complicated with malignant ascites can safely and effectively control the generation of ascites,improve the quality of life and prolong the survival of patients.

关 键 词：胃癌 恶性腹腔积液 重组人5型腺病毒 顺铂 临床疗效 

分 类 号：R735.2[医药卫生—肿瘤]